Pfizer Partners With GSK to Develop PCMM Prototype

Pfizer has entered into a multi-year partnership with GlaxoSmithKline to build on former’s existing portable, continuous, miniature and modular prototype for oral solid dose pharmaceutical development and manufacturing. The prototype is an autonomous and transportable pod that accelerates the speed of tablet production.

Under the deal, the two companies will create the next-generation design of Pfizer’s current PCMM prototype. Financial terms of the deal were not disclosed.

Pfizer spokesman Dean Mastrojohn says the initial phase of the collaboration will focus on the miniaturization of the oral solid dose processing equipment, enabling it to be deployed in a significantly smaller POD —  a portable, autonomous space — and  more existing facility spaces.

He adds that the companies will conduct design work needed to add continuous film coating and encapsulation to the prototype.